129 related articles for article (PubMed ID: 32242853)
1. ASSOCIATIONS BETWEEN EFFICACY OF THE THERAPY AND CIRCADIAN FLUCTUATIONS OF ENDOTHELIAL NITRIC OXIDE SYNTHASE WITH TOLL-LIKE RECEPTORS 2 EXPRESSION, AND NOS3 POLYMORPHISM IN FEMALES WITH RHEUMATOID ARTHRITIS.
Zaichko K; Stanislavchuk M; Zaichko N; Khomenko V
Georgian Med News; 2020 Feb; (299):93-100. PubMed ID: 32242853
[TBL] [Abstract][Full Text] [Related]
2. Circadian Rhythms of Endothelial Nitric Oxide Synthase and Toll-like Receptors 2 Production in Females with Rheumatoid Arthritis Depending on NOS3 Gene Polymorphism.
Zaichko K; Zaichko N; Maievskyi O; Korotkyi O; Falalyeyeva T; Fagoonee S; Pellicano R; Abenavoli L; Stanislavchuk M
Rev Recent Clin Trials; 2020; 15(2):145-151. PubMed ID: 32297585
[TBL] [Abstract][Full Text] [Related]
3. Circadian fluctuations of endothelial nitric oxide synthase activity in females with rheumatoid arthritis: a pilot study.
Zaichko K; Stanislavchuk M; Zaichko N
Rheumatol Int; 2020 Apr; 40(4):549-554. PubMed ID: 32025851
[TBL] [Abstract][Full Text] [Related]
4. Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis.
Gonzalez-Gay MA; Llorca J; Palomino-Morales R; Gomez-Acebo I; Gonzalez-Juanatey C; Martin J
Clin Exp Rheumatol; 2009; 27(1):116-9. PubMed ID: 19327239
[TBL] [Abstract][Full Text] [Related]
5. [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis].
Liu SY; Yang L; Zhang L; Zhang X; He YJ
Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1018-22. PubMed ID: 24503398
[TBL] [Abstract][Full Text] [Related]
6. The -786C/T single-nucleotide polymorphism in the promoter of the gene for endothelial nitric oxide synthase: insensitivity to physiologic stimuli as a risk factor for rheumatoid arthritis.
Melchers I; Blaschke S; Hecker M; Cattaruzza M
Arthritis Rheum; 2006 Oct; 54(10):3144-51. PubMed ID: 17009241
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
8. Statistically verified methods for determining predictors of development of arterial hypertension depending on endothelial nitric oxide synthase T786C gene promoter polymorphism using lipid profile indicators.
Pidruchna S; Shmanko V; Hnizdyukh R; Sverstiuk A; Lykhatskyy P; Kuzmak I; Yaroshenko T; Bandas I; Vasylyshyn N; Ostrivka O; Mudra A; Palytsia L; Letnyak N; Tokarskyy O
Endocr Regul; 2024 Jan; 58(1):138-143. PubMed ID: 38861536
[No Abstract] [Full Text] [Related]
9. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
11. Baseline adenosine receptor mRNA expression in blood as predictor of response to methotrexate therapy in patients with rheumatoid arthritis.
Singh A; Misra R; Aggarwal A
Rheumatol Int; 2019 Aug; 39(8):1431-1438. PubMed ID: 31203399
[TBL] [Abstract][Full Text] [Related]
12. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
[TBL] [Abstract][Full Text] [Related]
13. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between CXCL9 and CXCL10 gene polymorphisms and the outcome of rheumatoid arthritis treatment with methotrexate.
Kotrych D; Dziedziejko V; Safranow K; Pawlik A
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3037-40. PubMed ID: 26367725
[TBL] [Abstract][Full Text] [Related]
16. High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients.
Tan W; Wang F; Guo D; Ke Y; Shen Y; Lv C; Zhang M
Int J Rheum Dis; 2016 May; 19(5):482-9. PubMed ID: 24863583
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
19. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
20. [The influence of IL-6 polymorphism on efficacy of treatment of rheumatoid arthritis patients with methotrexate and prednisone].
Pawlik A; Czerny B; Dabrowska-Zamojcin E; Górnik W; Poziomkowska I; Gawrońska-Szklarz B; Herczyńska M
Pol Arch Med Wewn; 2005 Sep; 114(3):843-7. PubMed ID: 16708557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
